Gevo, Inc. (GEVO) Cash Flow Statement
Gevo, Inc. (GEVO) generated -$16.2M of operating cash flow over the twelve months to 2026-06-30, spent $40.4M on capital expenditure and had free cash flow of -$56.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GEVOGevo, Inc.Follow GEVO — free
—
Price chart with a free account
- Market cap
- 286.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -33.6 | -68.1 | -47.0 | -39.0 | -28.2 | -20.5 | -20.6 | -15.9 | -20.8 | -19.3 | -48.3 | -44.3 | -53.7 | -57.4 | -13.4 | -16.2 | |
| Capital expenditure | 8.0 | 52.4 | 9.8 | 4.9 | 1.5 | 5.9 | 1.9 | 2.2 | 6.5 | 6.2 | 56.8 | 84.1 | 54.5 | 51.1 | 30.1 | -40.4 | |
| Free cash flow | -41.6 | -120.5 | -56.9 | -43.9 | -29.6 | -26.5 | -22.5 | -18.1 | -27.3 | -25.6 | -105.0 | -128.4 | -108.2 | -108.5 | -43.5 | -56.7 | |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.7 | — | — | |
| Stock-based compensation | 6.8 | 8.0 | 3.9 | 2.9 | 2.6 | 0.9 | 0.4 | 0.7 | 1.3 | 2.1 | 9.9 | 17.4 | 17.1 | 14.7 | 9.2 | — |
USD millions · SEC XBRL
Gevo, Inc. — questions
- What is Gevo, Inc.'s operating cash flow?
- -$16.2M over the twelve months to 2026-06-30.
- How much does Gevo, Inc. spend on capital expenditure?
- $40.4M over the twelve months to 2026-06-30.
- What is Gevo, Inc.'s free cash flow?
- -$56.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Gevo, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.